Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
PTC Therapeutics, Inc. NASDAQ:PTCT | $5.30B | $63.49 | Undervalued | -35.0 | -21.29% |
Edgewise Therapeutics, Inc. NASDAQ:EWTX | $4.94B | $45.93 | Not rated | -21.9 | +89.71% |
Dyne Therapeutics, Inc. NASDAQ:DYN | $3.22B | $17.16 | Not rated | -7.2 | -23.57% |
Sarepta Therapeutics, Inc. NASDAQ:SRPT | $1.72B | $16.07 | Undervalued | 27.8 | -15.31% |
MeiraGTx Holdings plc NASDAQ:MGTX | $881.67M | $9.18 | Not rated | -7.4 | +9.16% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $675.64M | $12.23 | Not rated | -4.0 | +6.94% |
Capricor Therapeutics, Inc. NASDAQ:CAPR | $551.90M | $9.53 | Not rated | -13.9 | +49.11% |
Neurogene Inc. NASDAQ:NGNE | $378.15M | $23.93 | Not rated | -7.1 | +8.15% |
PepGen Inc. NASDAQ:PEPG | $301.98M | $4.36 | Not rated | -1.6 | -32.40% |
Continue the stock analysis
Jump to another research area for this company.